Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.

Cancer cell - 1 Feb 2005

Mohi M Golam, Williams Ifor R, Dearolf Charles R, Chan Gordon, Kutok Jeffery L, Cohen Sarah, Morgan Kelly, Boulton Christina, Shigematsu Hirokazu, Keilhack Heike, Akashi Koichi, Gilliland D Gary, Neel Benjamin G

Abstract excerpt

The SH2-containing tyrosine phosphatase Shp2 (PTPN11) is required for growth factor and cytokine signaling. Germline Shp2 mutations cause Noonan Syndrome (NS), which is associated with increased risk of juvenile myelomonocytic leukemia (JMML). Somatic Shp2 mutations occur in sporadic JMML and oth...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow Cells
Share to Granulocyte-Macrophage Colony-Stimulating Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-3

Share to Leukemia

Share to Neoplasms, Experimental

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to Protein Tyrosine Phosphatases

Share to Retroviridae

Source

Identifiers

PMID: 15710330
DOI: 10.1016/j.ccr.2005.01.010

Genes

PTPN11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-15710330-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.PMID 15710330Read ↗

Shp2 function in hematopoietic stem cell biology and leukemogenesisSemantic proximity Read ↗

A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells.Semantic proximity Read ↗

SHP-2 and myeloid malignancies.Semantic proximity Read ↗

Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.Semantic proximity Read ↗

Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.Semantic proximity Read ↗

Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT.Semantic proximity Read ↗

SHP2 sails from physiology to pathology.Semantic proximity Read ↗

The tyrosine phosphatase Shp2 (PTPN11) in cancer.Semantic proximity Read ↗

Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.Semantic proximity Read ↗

Targeting SHP2 phosphatase in hematological malignancies.Semantic proximity Read ↗

Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemiaSemantic proximity Read ↗

Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.